Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Arrowhead Pharmaceuticals Corp (ARWR) May Be Worth $75-$90 in a Sale - Cantor Fitzgerald
November 26, 2019 1:44 PM ESTCantor Fitzgerald analyst Alethia Young said Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) may be worth $75-$90 in a sale. The analyst reiterated a Neutral rating and $50 price target.
... MoreArrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
November 25, 2019 4:20 PM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $43.29 million versus the consensus estimate of $41.48 million.
Fiscal Year 2019 revenue was $168.796 million, EPS was $0.69.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More